Molecular mechanisms and therapeutic strategies for levodopa-induced dyskinesia in Parkinson's disease: a perspective through preclinical and clinical evidence
R Bandopadhyay, N Mishra, R Rana, G Kaur… - Frontiers in …, 2022 - frontiersin.org
Parkinson's disease (PD) is the second leading neurodegenerative disease that is
characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been …
characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been …
New insights into pathogenesis of l-DOPA-induced dyskinesia
C Zheng, F Zhang - Neurotoxicology, 2021 - Elsevier
Parkinson's disease (PD) is a progressive and self-propelling neurodegenerative disorder,
which is characterized by motor symptoms, such as rigidity, tremor, slowness of movement …
which is characterized by motor symptoms, such as rigidity, tremor, slowness of movement …
Current knowledge on the background, pathophysiology and treatment of levodopa-induced dyskinesia—literature review
M Hutny, J Hofman, A Klimkowicz-Mrowiec… - Journal of clinical …, 2021 - mdpi.com
Levodopa remains the primary drug for controlling motor symptoms in Parkinson's disease
through the whole course, but over time, complications develop in the form of dyskinesias …
through the whole course, but over time, complications develop in the form of dyskinesias …
D2 autoreceptor switches CB2 receptor effects on [3H]‐dopamine release in the striatum
G López‐Ramírez, R Sánchez‐Zavaleta… - Synapse, 2020 - Wiley Online Library
Abstract CB2 receptors (CB2R) are expressed in midbrain neurons. To evidence the control
of dopamine release in dorsal striatum by CB2R, we performed experiments of [3H] …
of dopamine release in dorsal striatum by CB2R, we performed experiments of [3H] …
Neuroanatomical and microglial alterations in the striatum of levodopa-treated, dyskinetic hemi-parkinsonian rats
EJR Fletcher, CJ Finlay, A Amor Lopez… - Frontiers in …, 2020 - frontiersin.org
Dyskinesia associated with chronic levodopa treatment in Parkinson's disease is associated
with maladaptive striatal plasticity. The objective of this study was to examine whether …
with maladaptive striatal plasticity. The objective of this study was to examine whether …
Coexistence of D3R typical and atypical signaling in striatonigral neurons during dopaminergic denervation. Correlation with D3nf expression changes
B Campos Campos, A Ávalos‐Fuentes… - Synapse, 2020 - Wiley Online Library
Dopamine D3R are widely expressed in basal ganglia where interact with D1R. D3R
potentiate cAMP accumulation and GABA release stimulated by D1R in striatonigral neurons …
potentiate cAMP accumulation and GABA release stimulated by D1R in striatonigral neurons …
Investigating the Role of Dopamine D1 Receptor and D3 Receptor Cooperativity in Dyskinesia
K Lanza - 2020 - search.proquest.com
Parkinson's Disease (PD) results in motor deficits which are symptomatically treated with
levodopa (L-DOPA). However, chronic use of L-DOPA inevitably leads to the development of …
levodopa (L-DOPA). However, chronic use of L-DOPA inevitably leads to the development of …
Efeito antidiscinético do MRS2500, antagonista dos receptores P2Y1, em ratos com parkinsonismo experimental induzido por 6-OHDA e tratados com L-DOPA
ATA Silva - 2021 - repositorio.ufc.br
RESUMO EFEITO ANTIDISCINÉTICO DO MRS2500, ANTAGONISTA DOS RECEPTORES
P2Y1, EM RATOS COM PARKINSONISMO EXPERIMENTAL INDUZIDO POR 6-OHDA E …
P2Y1, EM RATOS COM PARKINSONISMO EXPERIMENTAL INDUZIDO POR 6-OHDA E …